Nestle SA, the world’s biggest food company, said it will expand its skincare unit in North America by paying $1.4 billion in cash for commercial rights to sell some Valeant Pharmaceuticals Inc. products.

The purchase includes corrective facial aesthetic treatments Restylane, Perlane and Emervel in the U.S. and Canada, as well as Dysport, an aesthetic dermatology treatment. Nestle, whose Galderma unit already sells those medicines outside North America, will also acquire global rights for Sculptra.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.